Profile
Sector:
HealthcareCountry:
United StatesIPO:
03 May 1993Website:
http://www.anika.comNext earnings report:
31 October 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 4 min agoDividend
Analysts recommendations
Institutional Ownership
ANIK Latest News
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago.
Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds
Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications Cheryl Blanchard - President & Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Mike Petusky - Barrington Research George Sellers - Stephens Inc Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.
The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What type of business is Anika Therapeutics?
Anika Therapeutics, Inc. is an American manufacturer of drugs for preserving and restoring joints. The company was founded in 1992, with headquarters in Bedford, Massachusetts. Anika's proprietary technologies for modifying hyaluronic acid, which are protected by patents, allow for the effective alteration and adaptation of product properties. Anika's products include drugs for relieving joint pain; drugs, implants, surgical instruments for preserving and restoring joints; products for wound care, treatment of ENT diseases; ophthalmic drugs.
What sector is Anika Therapeutics in?
Anika Therapeutics is in the Healthcare sector
What industry is Anika Therapeutics in?
Anika Therapeutics is in the Drug Manufacturers - Specialty & Generic industry
What country is Anika Therapeutics from?
Anika Therapeutics is headquartered in United States
When did Anika Therapeutics go public?
Anika Therapeutics initial public offering (IPO) was on 03 May 1993
What is Anika Therapeutics website?
https://www.anika.com
Is Anika Therapeutics in the S&P 500?
No, Anika Therapeutics is not included in the S&P 500 index
Is Anika Therapeutics in the NASDAQ 100?
No, Anika Therapeutics is not included in the NASDAQ 100 index
Is Anika Therapeutics in the Dow Jones?
No, Anika Therapeutics is not included in the Dow Jones index
When was Anika Therapeutics the previous earnings report?
No data
When does Anika Therapeutics earnings report?
The next expected earnings date for Anika Therapeutics is 31 October 2024